The mechanism and mitigation of niacin-induced flushing

International Journal of Clinical Practice

Volumn 63, Issue 9, 2009, Pages 1369-1377

  Kamanna, V S ^b   Ganji, S H ^b   Kashyap, M L ^a  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE; ALANINE AMINOTRANSFERASE; ARACHIDONIC ACID; ASPARTATE AMINOTRANSFERASE; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 109A; IBUPROFEN; INDOMETACIN; LAROPIPRANT; NAPROXEN; NICOTINIC ACID; NICOTINIC ACID DERIVATIVE; NICOTINIC ACID PLUS SIMVASTATIN; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHODIESTERASE INHIBITOR; PHOSPHOLIPASE A2; PLACEBO; PROSTACYCLIN; PROSTAGLANDIN D2; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; RETINOIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEROTONIN UPTAKE INHIBITOR; THROMBOXANE A2; UNCLASSIFIED DRUG; ANTILIPEMIC AGENT; DELAYED RELEASE FORMULATION; IMMUNOGLOBULIN RECEPTOR; PROSTAGLANDIN; PROSTAGLANDIN D2 RECEPTOR; PROSTAGLANDIN RECEPTOR; PROSTAGLANDIN RECEPTOR BLOCKING AGENT;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BEDTIME DOSAGE; CAPILLARY; CLINICAL EVALUATION; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; DRUG TOLERANCE; DRUG WITHDRAWAL; DYSLIPIDEMIA; FLUSHING; HISTAMINE RELEASE; HUMAN; LANGERHANS CELL; LIVER TOXICITY; MEDICAL RESEARCH; MOLECULAR MECHANICS; NEUROTRANSMITTER RELEASE; NONHUMAN; PREMEDICATION; PRIORITY JOURNAL; RECEPTOR BLOCKING; REPEATED DRUG DOSE; REVIEW; SIDE EFFECT; SUSTAINED DRUG RELEASE; THROMBOCYTE AGGREGATION; VASOCONSTRICTION; VASODILATATION; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DELAYED RELEASE FORMULATION; DRUG EFFECTS; DYSLIPIDEMIAS; METABOLISM; PATIENT EDUCATION; PREVENTION AND CONTROL;

ARACHIDONIC ACID; DELAYED-ACTION PREPARATIONS; DYSLIPIDEMIAS; FLUSHING; HUMANS; HYPOLIPIDEMIC AGENTS; NIACIN; PATIENT EDUCATION AS TOPIC; PROSTAGLANDIN ANTAGONISTS; PROSTAGLANDINS; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN; VASOCONSTRICTION; VASODILATION;

EID: 68949215867     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2009.02099.x     Document Type: Review

References (74)

1. Capuzzi DM, Guyton JR, Morgan JM et al. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am J Cardiol 1998 82 : 74U 81U.
2. Carlson LA, Hamsten A, Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med 1989 226 : 271 276.
3. Guyton JR, Goldberg AC, Kreisberg RA, Sprecher DL, Superko HR, O'Connor CM. Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol 1998 82 : 737 743.
4. Guyton JR, Blazing MA, Hagar J et al. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group. Arch Intern Med 2000 160 : 1177 1184.
5. Knopp RH, Alagona P, Davidson M et al. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism 1998 47 : 1097 1104.
6. Berglund L, Ramakrishnan R. Lipoprotein(a): an elusive cardiovascular risk factor. Arterioscler Thromb Vasc Biol 2004 24 : 2219 2226.
7. Superko HR, McGovern ME, Raul E, Garrett B. Differential effect of two nicotinic acid preparations on low-density lipoprotein subclass distribution in patients classified as low-density lipoprotein pattern A, B, or I. Am J Cardiol 2004 94 : 588 594.
8. Wahlberg G, Walldius G, Olsson AG, Kirstein P. Effects of nicotinic acid on serum cholesterol concentrations of high density lipoprotein subfractions HDL2 and HDL3 in hyperlipoproteinaemia. J Intern Med 1990 228 : 151 157.
9. Sakai T, Kamanna VS, Kashyap ML. Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL-cholesterol. Arterioscler Thromb Vasc Biol 2001 21 : 1783 1789.
10. Clofibrate and niacin in coronary heart disease. JAMA 1975 231 : 360 381.
11. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004 110 : 3512 3517.
12. Benyó Z, Gille A, Kero J et al. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. J Clin Invest 2005 115 : 3634 3640.
13. Benyó Z, Gille A, Bennett CL, Clausen BE, Offermanns S. Nicotinic acid-induced flushing is mediated by activation of epidermal langerhans cells. Mol Pharmacol 2006 70 : 1844 1849.
14. Goldberg A, Alagona P Jr., Capuzzi DM et al. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol 2000 85 : 1100 1105.
15. Stern RH, Spence JD, Freeman DJ, Parbtani A. Tolerance to nicotinic acid flushing. Clin Pharmacol Ther 1991 50 : 66 70.
16. Ganji SH, Tavintharan S, Zhu D, Xing Y, Kamanna VS, Kashyap ML. Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. J Lipid Res 2004 45 : 1835 1845.
17. Blum CB, Levy RI, Eisenberg S, Hall M III., Goebel RH, Berman M. High density lipoprotein metabolism in man. J Clin Invest 1977 60 : 795 807.
18. Zhang LH, Kamanna VS, Zhang MC, Kashyap ML. Niacin inhibits surface expression of ATP synthase beta chain in HepG2 cells: implications for raising HDL. J Lipid Res 2008 49 : 1195 1201.
19. Martinez LO, Jacquet S, Esteve JP et al. Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. Nature 2003 421 : 75 79.
20. Lorenzen A, Stannek C, Lang H, Andrianov V, Kalvinsh I, Schwabe U. Characterization of a G protein-coupled receptor for nicotinic acid. Mol Pharmacol 2001 59 : 349 357.
21. Tunaru S, Kero J, Schaub A et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med 2003 9 : 352 355.
22. Wise A, Foord SM, Fraser NJ et al. Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem 2003 278 : 9869 9874.
23. Lorenzen A, Stannek C, Burmeister A, Kalvinsh I, Schwabe U. G protein-coupled receptor for nicotinic acid in mouse macrophages. Biochem Pharmacol 2002 64 : 645 648.
24. Kamanna VS, Kashyap ML. Nicotinic Acid (niacin) receptor agonists: will they be useful therapeutic agents? Am J Cardiol 2007 100 : S53 61.
25. Ganji SH, Qin S, Zhang L, Kamanna VS, Kashyap ML. Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells. Atherosclerosis 2009 202 : 68 75. [Epub 2008 May 9.] PMID: 18550065 [PubMed - as supplied by publisher].
26. Morrow JD, Parsons WG III., Roberts LJ II. Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid. Prostaglandins 1989 38 : 263 274.
27. Plummer NA, Hensby CN, Black AK, Greaves MW. Prostaglandin activity in sustained inflammation of human skin before and after aspirin. Clin Sci Mol Med 1977 52 : 615 620.
28. Andersson RG, Aberg G, Brattsand R, Ericsson E, Lundholm L. Studies on the mechanism of flush induced by nicotinic acid. Acta Pharmacol Toxicol (Copenh) 1977 41 : 1 10.
29. Morgan JM, Capuzzi DM, Guyton JR. A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. Am J Cardiol 1998 82 : 29U 34U.
30. Lin LL, Lin AY, Knopf JL. Cytosolic phospholipase A2 is coupled to hormonally regulated release of arachidonic acid. Proc Natl Acad Sci U S A 1992 89 : 6147 6151.
31. Svedmyr N, Heggelund A, Aberg G. Influence of indomethacin on flush induced by nicotinic acid in man. Acta Pharmacol Toxicol (Copenh) 1977 41 : 397 400.
32. Eklund B, Kaijser L, Nowak J, Wennmalm A. Prostaglandins contribute to the vasodilation induced by nicotinic acid. Prostaglandins 1979 17 : 821 830.
33. Kaijser L, Eklund B, Olsson AG, Carlson LA. Dissociation of the effects of nicotinic acid on vasodilatation and lipolysis by a prostaglandin synthesis inhibitor, indomethacin, in man. Med Biol 1979 57 : 114 117.
34. Coleman RA, Smith WL, Narumiya S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 1994 46 : 205 229.
35. Lee SL, Levitsky S, Feinberg H. Endogenous vasoconstrictor prostanoids: role in serotonin and vasopressin-induced coronary vasoconstriction. J Pharmacol Exp Ther 1991 258 : 292 298.
36. Nagata K, Hirai H. The second PGD (2) receptor CRTH2: structure, properties, and functions in leukocytes. Prostaglandins Leukot Essent Fatty Acids 2003 69 : 169 177.
37. Sugimoto Y, Narumiya S. Prostaglandin E receptors. J Biol Chem 2007 282 : 11613 11617.
38. Kabashima K, Narumiya S. The DP receptor, allergic inflammation and asthma. Prostaglandins Leukot Essent Fatty Acids 2003 69 : 187 194.
39. Arehart E, Gleim S, Kasza Z, Fetalvero KM, Martin KA, Hwa J. Prostacyclin, atherothrombosis, and cardiovascular disease. Curr Med Chem 2007 14 : 2161 2169.
40. Hata AN, Breyer RM. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther 2004 103 : 147 166.
41. Giles H, Leff P. The biology and pharmacology of PGD2. Prostaglandins 1988 35 : 277 300.
42. Spannhake EW, Hyman AL, Kadowitz PJ. Bronchoactive metabolites of arachidonic acid and their role in airway function. Prostaglandins 1981 22 : 1013 1026.
43. Nozaki S, Kihara S, Kubo M, Kameda K, Matsuzawa Y, Tarui S. Increased compliance of niceritrol treatment by addition of aspirin: relationship between changes in prostaglandins and skin flushing. Int J Clin Pharmacol Ther Toxicol 1987 25 : 643 647.
44. Morrow JD, Awad JA, Oates JA, Roberts LJ II. Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans. J Invest Dermatol 1992 98 : 812 815.
45. Whatling C, McPheat W, Herslof M. The potential link between atherosclerosis and the 5-lipoxygenase pathway: investigational agents with new implications for the cardiovascular field. Expert Opin Investig Drugs 2007 16 : 1879 1893.
46. Larkin SW, Fraser L, Showell HJ, Williams TJ, Warren JB. Prolonged microvascular vasodilation induced by leukotriene B4 in human skin is cyclooxygenase independent. J Pharmacol Exp Ther 1995 272 : 392 398.
47. Saareks V, Mucha I, Sievi E, Riutta A. Nicotinic acid and pyridoxine modulate arachidonic acid metabolism in vitro and ex vivo in man. Pharmacol Toxicol 1999 84 : 274 280.
48. Davidson MH. Niacin therapy: an evolving paradigm for the management of mixed dyslipidemia and low high-density lipoprotein cholesterol. Am J Cardiol 2008 101 (Suppl. 1) S14 9.
49. Svedmyr N, Harthon L, Lundholm L. The relationship between the plasma concentration of free nicotinic acid and some of its pharmacologic effects in man. Clin Pharmacol Ther 1969 10 : 559 570.
50. Pieper JA. Understanding niacin formulations. Am J Manag Care 2002 8 : S308 14.
51. Piepho RW. The pharmacokinetics and pharmacodynamics of agents proven to raise high-density lipoprotein cholesterol. Am J Cardiol 2000 86 : 35L 40L.
52. McKenney J. Niacin for dyslipidemia: considerations in product selection. Am J Health Syst Pharm 2003 60 : 995 1005.
53. Gibbons LW, Gonzalez V, Gordon N, Grundy S. The prevalence of side effects with regular and sustained-release nicotinic acid. Am J Med 1995 99 : 378 385.
54. Knopp RH, Ginsberg J, Albers JJ et al. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism 1985 34 : 642 650.
55. McKenney JM, Proctor JD, Harris S, Chinchili VM. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. JAMA 1994 271 : 672 677.
56. Christensen NA, Achor RW, Berge KG, Mason HL. Nicotinic acid treatment of hypercholesteremia. Comparison of plain and sustained-action preparations and report of two cases of jaundice. JAMA 1961 177 : 546 550.
57. Meyers CD, Carr MC, Park S, Brunzell JD. Varying cost and free nicotinic acid content in over-the-counter niacin preparations for dyslipidemia. Ann Intern Med 2003 139 : 996 1002.
58. Norris RB. "Flush-free niacin": dietary supplement may be "benefit-free". Prev Cardiol 2006 9 : 64 65.
59. Cefali EA, Simmons PD, Stanek EJ, Shamp TR. Improved control of niacin-induced flushing using an optimized once-daily, extended-release niacin formulation. Int J Clin Pharmacol Ther 2006 44 : 633 640.
60. NIASPAN® [package insert]. Abbott Park, IL : Abbott Laboratories, 2007.
61. Hunninghake DB, McGovern ME, Koren M et al. A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin. Clin Cardiol 2003 26 : 112 118.
62. Kashyap ML, McGovern ME, Berra K et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol 2002 89 : 672 678.
63. McKenney JM, Jones PH, Bays HE et al. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). Atherosclerosis 2007 192 : 432 437.
64. Ballantyne CM, Davidson MH, McKenney J, Keller LH, Bajorunas DR, Karas RH. Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). Am J Cardiol 2008 101 : 1428 1436.
65. Ballantyne CM, Davidson MH, McKenney JM, Keller LH, Bajorunas DR, Karas RH. Comparison of the efficacy and safety of a combination tablet of niacin extended-release and simvastatin with simvastatin 80 mg monotherapy: the SEACOAST II (high dose) study. J Clin Lipidol 2008 2 : 79 90.
66. Karas RH, Kashyap ML, Knopp RH, Keller LH, Bajournas DR, Davidson MH. Long-term safety and efficacy of a combination of niacin extended-release and simvastatin in patients with dyslipidemia. Am J Cardiovasc Drugs 2008 8 : 69 81.
67. Cefali EA, Simmons PD, Stanek EJ, McGovern ME, Kissling CJ. Aspirin reduces cutaneous flushing after administration of an optimized extended-release niacin formulation. Int J Clin Pharmacol Ther 2007 45 : 78 88.
68. Thakkar RB, Kashyap ML, Lewin AJ, Krause SL, Jiang P, Padley RJ. Acetylsalicylic acid reduces niacin extended-release-induced flushing in patients with dyslipidemia. Am J Cardiovasc Drugs 2009 9 : 69 79.
69. Dunn RT, Ford MA, Rindone JP, Kwiecinski FA. Low-dose aspirin and ibuprofen reduce the cutaneous reactions following niacin administration. Am J Ther 1995 2 : 478 480.
70. Jungnickel PW, Maloley PA, Vander Tuin EL, Peddicord TE, Campbell JR. Effect of two aspirin pretreatment regimens on niacin-induced cutaneous reactions. J Gen Intern Med 1997 12 : 591 596.
71. Lai E, De Lepeleire I, Crumley TM et al. Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1. Clin Pharmacol Ther 2007 81 : 849 857.
72. Cheng K, Wu TJ, Wu KK et al. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci U S A 2006 103 : 6682 6687.
73. Hirata F, Schiffmann E, Venkatasubramanian K, Salomon D, Axelrod J. A phospholipase A2 inhibitory protein in rabbit neutrophils induced by glucocorticoids. Proc Natl Acad Sci U S A 1980 77 : 2533 2536.
74. Newton R, Kuitert LM, Slater DM, Adcock IM, Barnes PJ. Cytokine induction of cytosolic phospholipase A2 and cyclooxygenase-2 mRNA is suppressed by glucocorticoids in human epithelial cells. Life Sci 1997 60 : 67 78.